Predict your next investment

Venture Capital

See what CB Insights has to offer

Investments

33

Portfolio Exits

6

About Lurie Investment Fund

Lurie Investment Fund, LLC is the venture capital arm of the Ann and Robert H. Lurie Foundation specializing in venture capital and private equity investments. The firm seeks to invest in the biomedical community, mainly in medical devices, therapeutics, diagnostics and services, nanotechnology, and MEMS technology. Lurie Investment Fund, LLC is based in Chicago, Illinois.

Lurie Investment Fund Headquarter Location

2 North Riverside Plaza Street Suite 1500

Chicago, Illinois, 60606,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Lurie Investment Fund

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Lurie Investment Fund in 1 Expert Collection, including Vitamin & Supplement Startups.

V

Vitamin & Supplement Startups

237 items

Lurie Investment Fund Investments

33 Investments

Lurie Investment Fund has made 33 investments. Their latest investment was in Viamet Pharmaceuticals as part of their Series D on October 10, 2014.

CBI Logo

Lurie Investment Fund Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/21/2014

Series D

Viamet Pharmaceuticals

$60M

No

3

3/12/2014

Series C - II

Viamet Pharmaceuticals

$10M

No

1

6/17/2013

Series C

Viamet Pharmaceuticals

$10M

No

1

1/5/2013

Series E

Subscribe to see more

$99M

Subscribe to see more

10

2/28/2012

Series E - II

Subscribe to see more

$99M

Subscribe to see more

0

Date

10/21/2014

3/12/2014

6/17/2013

1/5/2013

2/28/2012

Round

Series D

Series C - II

Series C

Series E

Series E - II

Company

Viamet Pharmaceuticals

Viamet Pharmaceuticals

Viamet Pharmaceuticals

Subscribe to see more

Subscribe to see more

Amount

$60M

$10M

$10M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

1

1

10

0

Lurie Investment Fund Portfolio Exits

6 Portfolio Exits

Lurie Investment Fund has 6 portfolio exits. Their latest portfolio exit was Viamet Pharmaceuticals on January 03, 2018.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/3/2018

Acq - Fin

2

9/3/2013

Acquired

Subscribe to see more

Subscribe to see more

10

12/6/2009

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

10/24/2009

Acquired

Subscribe to see more

Subscribe to see more

10

2/9/2007

IPO

Subscribe to see more

$99M

Subscribe to see more

0

Date

1/3/2018

9/3/2013

12/6/2009

10/24/2009

2/9/2007

Exit

Acq - Fin

Acquired

Acquired

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

0

Lurie Investment Fund Team

1 Team Member

Lurie Investment Fund has 1 team member, including current President, Ann Lurie.

Name

Work History

Title

Status

Ann Lurie

President

Current

Name

Ann Lurie

Work History

Title

President

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.